Silodosin and Tadalafil Combination Therapy for BPH/LUTS

Guideline-Based Recommendations

The American Urological Association provides a Moderate Recommendation (Evidence Level: Grade C) stating that clinicians should not offer the combination of low-dose daily 5 mg tadalafil with alpha-blockers for treating LUTS/BPH, as it offers no advantages in symptom improvement over either agent alone 1, 2
The European Association of Urology 2023 guidelines note that while PDE5 inhibitors combined with alpha-blockers show statistical improvements in some parameters, the clinical significance must be weighed against increased adverse events 4

The combination of silodosin with tadalafil creates additive blood pressure-lowering effects, with highest risk in patients with cardiovascular disease, those taking antihypertensive medications, or those with intravascular volume depletion 3
Higher rates of dizziness, headache, dyspepsia, back pain, and nasal congestion occur with combination therapy compared to monotherapy 1, 2

For patients with BPH/LUTS and ED, discontinue silodosin and switch to tadalafil 5 mg once daily as monotherapy, which treats both conditions with a single medication and avoids drug interaction risks 3, 6
Tadalafil 5 mg daily is FDA-approved for simultaneous treatment of both BPH/LUTS and ED, with expected IPSS reduction: -5.4 to -6.1 points vs -3.6 to -3.8 points with placebo 6, 7

Before prescribing tadalafil, verify absolute absence of nitrate use in any form due to risk of potentially fatal hypotension 7, 8
Assess cardiovascular fitness and screen for severe uncontrolled hypertension, recent stroke, recent MI, NYHA Class II-IV heart failure, or severe hepatic/renal insufficiency 4, 7, 8